MARKET

RLMD

RLMD

Relmada Therapeutics Inc
NASDAQ
7.04
-0.17
-2.36%
After Hours: 7.04 0 0.00% 16:10 05/22 EDT
OPEN
7.26
PREV CLOSE
7.21
HIGH
7.50
LOW
7.01
VOLUME
668.68K
TURNOVER
--
52 WEEK HIGH
8.00
52 WEEK LOW
0.4354
MARKET CAP
738.43M
P/E (TTM)
-6.1404
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at RLMD last week (0511-0515)?
Weekly Report · 6d ago
Relmada Therapeutics Charts Ambitious NDV-01 Phase 3 Path
TipRanks · 05/14 00:28
Relmada Therapeutics files automatic mixed securities shelf
TipRanks · 05/13 21:24
Relmada Therapeutics Files For Mixed Shelf Offering, Size Not Disclosed
Benzinga · 05/13 20:56
RELMADA THERAPEUTICS INC: FILES FOR MIXED SHELF OFFERING, SIZE NOT DISCLOSED - SEC FILING
Reuters · 05/13 20:54
Piper Sandler Sticks to Its Buy Rating for Relmada Therapeutics (RLMD)
TipRanks · 05/13 11:36
Relmada targets mid-2026 Phase 3 RESCUE start backed by $234M cash runway through 2029
Seeking Alpha · 05/13 01:31
Wall Street Analysts Are Bullish on Top Healthcare Picks
TipRanks · 05/13 01:20
More
About RLMD
Relmada Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing therapies for central nervous system (CNS) and metabolic disorders. The Company is focused on the development of esmethadone (d-methadone, dextromethadone, REL-1017), an N-methyl-D-aspartate (NMDA) receptor antagonist. Esmethadone, an isomer of methadone, is a new chemical entity (NCE) that potentially addresses areas of high unmet medical need in the treatment of CNS diseases and other disorders. The Company’s lead program, REL-1017, is a NCE and novel NMDA receptor (NMDAR) channel blocker that preferentially targets hyperactive channels while maintaining physiological glutamatergic neurotransmission. Its lead product candidate, esmethadone, is being developed as a rapidly acting, oral agent for the treatment of depression and other potential indications. Sepranolone is its phase IIb ready neurosteroid developed for the potential treatment of Tourette syndrome and other compulsive disorders.

Webull offers Relmada Therapeutics Inc stock information, including NASDAQ: RLMD real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, RLMD stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading RLMD stock methods without spending real money on the virtual paper trading platform.